# Single Low Dose Tafenoquine to Reduce P. Falciparum Transmission in Mali (NECTAR2)

> **NCT04609098** · PHASE2 · COMPLETED · sponsor: **London School of Hygiene and Tropical Medicine** · enrollment: 80 (actual)

## Conditions studied

- Malaria, Falciparum

## Interventions

- **DRUG:** Dihydroartemisinin/Piperaquine
- **DRUG:** Tafenoquine 100mg [Arakoda]

## Key facts

- **NCT ID:** NCT04609098
- **Lead sponsor:** London School of Hygiene and Tropical Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-29
- **Primary completion:** 2020-12-02
- **Final completion:** 2020-12-23
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2022-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04609098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04609098, "Single Low Dose Tafenoquine to Reduce P. Falciparum Transmission in Mali (NECTAR2)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04609098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*